Price-to-Earnings Forward Twelve Months (F12M) Image Source: Zacks Investment Research The stock also appears cheaper in comparison to QGEN and ABT, which are trading at 19.36X and 21.02X, respectively. Investment Thesis Hologic's future growth prospects are highlighted by its impressive portfolio of products regardless of macroeconomic hurdles. In the Molecular Diagnostics business, the company has expanded both the worldwide Panther footprint and menu, with the BV and CV/TV assays and the Biotheranostics ...